NEW YORK: The German chemicals group's rejected $62 bln offer for the seed maker already appeared to violate one of its key principles: stick to projects whose returns beat the cost of capital.
Upping the price to win over Monsanto would take heroic sales-growth assumptions to stack up.
Comments
Comments are closed.